The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

Roche confirmed its full-year outlook with sales expected to increase in the mid-single-digit percent range at constant exchange rates. The firm added that EPS for full-year 2025 is expected to ...